BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

VALN

Valneva SE
Nasdaq · Biological products, (no diagnostic substances) (SIC 2836) · FY ends 31 Dec

Revenue, quarterly

$56M−1.7% year on year
$400M$200M$0
Q1 ’21Q2 ’22Q3 ’23Q3 ’24Q4 ’25
Company filings · 20-F filed 17 Mar 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

38.2%−3.7 pp year on year
60%40%20%0%
Q4 ’21Q4 ’22Q4 ’23Q4 ’24Q4 ’25
Company filings · 20-F filed 17 Mar 2026 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$129M−26.1% year on year
$400M$200M$0
Q1 ’21Q2 ’22Q3 ’23Q3 ’24Q4 ’25
Company filings · 20-F filed 17 Mar 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$66M
$100M$0−$100M−$200M−$300M
Q4 ’21Q4 ’22Q4 ’23Q4 ’24Q4 ’25
Company filings · 20-F filed 17 Mar 2026 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty